Van ECK Associates Corp Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Van ECK Associates Corp raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 8.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 58,666 shares of the biopharmaceutical company's stock after acquiring an additional 4,529 shares during the period. Van ECK Associates Corp's holdings in Alnylam Pharmaceuticals were worth $17,660,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Geode Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 6.1% in the fourth quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company's stock valued at $1,056,884,000 after purchasing an additional 151,480 shares during the period. Norges Bank acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter worth about $895,816,000. Orbis Allan Gray Ltd grew its holdings in Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock valued at $691,771,000 after buying an additional 486,489 shares during the period. Wellington Management Group LLP grew its holdings in Alnylam Pharmaceuticals by 9.0% in the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company's stock valued at $635,296,000 after buying an additional 174,482 shares during the period. Finally, Legal & General Group Plc increased its stake in shares of Alnylam Pharmaceuticals by 8.3% during the 4th quarter. Legal & General Group Plc now owns 961,496 shares of the biopharmaceutical company's stock valued at $382,339,000 after acquiring an additional 73,716 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ALNY shares. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 2nd. Sanford C. Bernstein reaffirmed an "outperform" rating and set a $376.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, August 25th. JPMorgan Chase & Co. decreased their price target on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Morgan Stanley lowered their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an "equal weight" rating for the company in a research note on Friday, July 31st. Finally, BMO Capital Markets started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, August 19th. They issued an "outperform" rating and a $318.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $386.14.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $237.10 on Monday. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $31.73 billion, a price-to-earnings ratio of 44.07 and a beta of 0.30. The firm's fifty day simple moving average is $262.62 and its 200 day simple moving average is $293.54. Alnylam Pharmaceuticals, Inc. has a twelve month low of $197.81 and a twelve month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm's quarterly revenue was up 66.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.51) EPS. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source